Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan

Transfusion

Volumn 53, Issue 7, 2013, Pages 1393-1404

  Taira, Rikizo ^a   Satake, Masahiro ^a   Momose, Shun'Ya ^a   Hino, Satoru ^a   Suzuki, Yoshiharu ^a   Murokawa, Hiroyuki ^a   Uchida, Shigeharu ^a   Tadokoro, Kenji ^a  

^a Japan

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; THROMBOCYTE CONCENTRATE;

ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD ANALYSIS; BLOOD COMPONENT; BLOOD DONOR; BLOOD SAFETY; BLOOD TRANSFUSION REACTION; CLINICAL DATA REPOSITORY; DISEASE COURSE; DNA SEQUENCE; HEPATITIS B VIRUS; JAPAN; LIMIT OF DETECTION; SCREENING; SEQUENCE ANALYSIS; TORQUE TENO VIRUS INFECTION; VIRUS LOAD;

BLOOD COMPONENT TRANSFUSION; BLOOD DONORS; HEPATITIS B; HEPATITIS B ANTIBODIES; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RISK;

EID: 84880247765     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03909.x     Document Type: Article

References (36)

1. Tanaka J, Koyama T, Mizui M, Uchida S, Katayama K, Matsuo J, Akita T, Nakashima A, Miyakawa Y, Yoshizawa H,. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology 2011; 54: 185-95.
2. Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaka R, Suzuki K, Miyakawa Y, Yoshizawa H,. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 2004; 47: 32-40.
3. Ohnuma H, Tanaka T, Yoshikawa A, Murokawa H, Minegishi K, Yamanaka R, Iizuka HY, Miyamoto M, Satoh S, Nakahira S, Tomono T, Murozuka T, Takeda Y, Doi Y, Mine H, Yokoyama S, Hirose T, Nishioka K,; Japanese Red Cross NAT Screening Research Group. The first large-scale nucleic acid amplification testing (NAT) of donated blood using multiplex reagent for simultaneous detection of HBV, HCV, and HIV-1 and significance of NAT for HBV. Microbiol Immunol 2001; 45: 667-72.
4. Allain JP,. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004; 86: 83-91.
5. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Zoulim F,. et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-7.
6. Mine H, Emura H, Miyamoto M, Tomono T, Minegishi K, Murokawa H, Yamanaka R, Yoshikawa A, Nishioka K,; Japanese Red Cross NAT Research Group. High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan. J Virol Methods 2003; 112: 145-51.
7. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K,. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007; 47: 1197-205.
8. Pharmaceutical and Food Safety Bureau, Blood and Blood Products Division. Guidelines for lookback study for blood products. Tokyo, Japan: Japanese Ministry of Health, Labour and Welfare; 2005. p. 2-26.
9. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH,; NHLBI-REDS NAT Study Group. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 254-64.
10. Satake M,. Infectious risks associated with the transfusion of blood components and pathogen inactivation in Japan. Int J Hematol 2004; 80: 306-10.
11. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K,; Japanese Red Cross NAT Screening Research Group. HBV NAT positive [corrected] blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005; 88: 77-86.
12. Kosaka Y, Takase K, Kojima M, Shimizu M, Inoue K, Yoshiba M, Tanaka S, Akahane Y, Okamoto H, Tsuda F, Miyakawa Y, Mayumi M,. Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 1991; 100: 1087-94.
13. Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, Tsuda F, Tanaka T, Okamoto H, Miyakawa Y, Mayumi M,. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122: 241-8.
14. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M,. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64: 1298-303.
15. Kurosaki M, Enomoto N, Asahina Y, Sakuma I, Ikeda T, Tozuka S, Izumi N, Marumo F, Sato C,. Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B. J Med Virol 1996; 49: 115-23.
16. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ,. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978; 298: 1379-83.
17. Iizuka H, Ohmura K, Ishijima A, Satoh K, Tanaka T, Tsuda F, Okamoto H, Miyakawa Y, Mayumi M,. Correlation between anti-HBc titers and HBV DNA in blood units without detectable HBsAg. Vox Sang 1992; 63: 107-11.
18. Japanese Red Cross Non-A, Non-B Hepatitis Research Group. Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of posttransfusion hepatitis. Lancet 1991; 338: 1040-1.
19. Nozawa Y, Ohto H,. An autopsy case of post-transfusion fulminant hepatitis B due to screened blood for anti-hepatitis B core. Kanzo 1993; 34: 433-6.
20. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F,. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007; 47: 2338-47.
21. McCullough J,. Pathogen inactivation: a new paradigm for preventing transfusion-transmitted infections. Am J Clin Pathol 2007; 128: 945-55.
22. Allain JP, Hewitt PE, Tedder RS, Williamson LM,. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haematol 1999; 107: 186-95.
23. Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Günther S, Hess G, Hüdig H, Kitchen A, Margolis H, Michel G, Trepo C, Will H, Zanetti A, Mushahwar I,. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 2000; 62: 450-5.
24. Gerlich WH, Wagner FF, Chudy M, Harritshoj LH, Lattermann A, Wienzek S, Glebe D, Saniewski M, Schüttler CG, Wend UC, Willems WR, Bauerfeind U, Jork C, Bein G, Platz P, Ullum H, Dickmeiss E,. HBsAg non-reactive HBV infection in blood donors: transmission and pathogenicity. J Med Virol 2007; 79: S32-S36.
25. Dreier J, Kröger M, Diekmann J, Götting C, Kleesiek K,. Intermittent HBV viremia in an anti-HBc and anti-HBs-positive blood donor. Transfus Med 2005; 15: 65-6.
26. Stramer SL, Zou S, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY,. Blood donation screening for hepatitis B virus markers in the era of nucleic acid testing: are all tests of value? Transfusion 2012; 52: 440-6.
27. Kino S, Tomoda Y, Itoh Y, Karasaki H, Kasai S,. Implementation of pre- and post-transfusion viral marker tests at Asahikawa medical college hospital. Jpn J Transfus Cell Ther 2009; 55: 21-8.
28. Hollinger FB, Dodd RY,. Hepatitis B virus traceback and lookback: factors to consider. Transfusion 2009; 49: 176-84.
29. Yang MH, Li L, Hung YS, Hung CS, Allain JP, Lin KS, Tsai SJ,. The efficacy of individual-donation and minipool testing to detect low-level hepatitis B virus DNA in Taiwan. Transfusion 2010; 50: 65-74.
30. Weber B, Melchior W, Gehrke R, Doerr HW, Berger A, Rabenau H,. Hepatitis B virus markers in anti-HBc only positive individuals. J Med Virol 2001; 64: 312-9.
31. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P,. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001; 34: 194-203.
32. Alhababi F, Sallam TA, Tong CY,. The significance of "anti-HBc only" in the clinical virology laboratory. J Clin Virol 2003; 27: 162-9.
33. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP,. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 2008; 48: 1022-5.
34. Inaba S, Ito A, Miyata Y, Ishii H, Kajimoto S, Tanaka M, Maruta A, Saito S, Yugi H, Hino M, Tadokoro K,. Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion. Transfusion 2006; 46: 2028-9.
35. Candotti D, Allain JP,. Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009; 51: 798-809.
36. Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, Yeh SH, Chen PJ, Chen DS,. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol 2006; 44: 39-46.